<DOC>
	<DOCNO>NCT01659138</DOCNO>
	<brief_summary>Primary Objective : To assess efficacy SAR339658 Secondary Objective : To assess safety SAR339658</brief_summary>
	<brief_title>Efficacy Safety SAR339658 Patients With Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description>The study period per patient include 4 week screen , 8 week treatment , 6 week post treatment safety follow-up , follow long term safety follow-up perform form phone interview 3 , 6 , 12 , 18 24 month last administration study medication . After completion 8-week treatment phase , patient may eligible enter long term safety study ( LTS12593 ) active treatment SAR339658 .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Inclusion criterion : Male Female ≥18 ≤70 year old History active ulcerative colitis least 3 month duration Active UC confirm colonoscopy flexible sigmoidoscopy screen period within 7 day prior randomization . Moderate severe ulcerative colitis time screening , confirm Mayo score ≥6 12 endoscopy subscore ≥2 despite treatment immunosuppressant and/or antitumor necrosis factor ( TNFs ) : Immunosuppressants : Patient must concurrent treatment inadequate response ( respond lose response ) intolerant immunosuppressant azathioprine , 6mercaptopurine , methotrexate . AND/OR TNFalpha antagonist : Patient must inadequate response lose response intolerant TNFalpha antagonists Fecal calprotectin ≥200mg/kg Patients corticosteroid must stable dose ≥2 week prior screen Patients azathioprine , 6 mercaptopurine methotrexate must treatment least 12 week prior screen ; stable dose ≥4 week prior screen Patients oral 5aminosalicylates , mesalamine sulfasalazine must stable dose ≥4 week prior screen Patients naïve antiTNF alpha nonresponder ( primary secondary ) intolerant antiTNF alpha Signed write informed consent Exclusion criterion : Patients Crohn 's Disease Diagnosis indeterminate colitis Patients stool sample positive ovum , parasite , positive culture aerobic pathogen include : Aeromonas , Plesiomonas , Shigella , Yersinia , Campylobacter E. Coli spp . positive Clostridium difficile B toxin stool . Patients prior colectomy anticipate colectomy participation study Presence ileal pouch ostomy Fulminant disease toxic megacolon Colonic dysplasia except adenoma Total Parenteral Nutrition Cyclosporine , mycophenolate mofetil , sirolimus ( rapamycin ) , thalidomide tacrolimus within 2 month prior screen Previous exposure natalizumab ( Tysabri® ) vedolizumab Antidiarrheals within 2 week prior screen Prednisone &gt; 40 mg/day ( equivalent ) Budesonide &gt; 9 mg/day Received intravenous corticosteroid within 2 week prior screen screen Rectally administer topical 5aminosalicylate corticosteroid within 4 week prior screen Received therapeutic enema suppository , require colonoscopy flexible sigmoidoscopy within 4 week prior screen screen Antibiotics ulcerative colitis gastrointestinal infection within 4 week prior screen Patient previously participate clinical trial GBR500 / SAR339658 Patient take investigational medication within 2 month 5 half life , ( whichever longer ) prior screen Use biologics treatment ulcerative colitis previous 8 week screen Requirement concomitant treatment could bias primary evaluation Pregnant breastfeed woman Women childbearing potential protect highly effective contraceptive method birth control Patient latent active tuberculosis ( TB ) define : Any sign symptom suggestive active TB upon medical history clinical examination Patients positive QuantiFERON TB Gold Test Chest radiograph within 3 month prior inclusion visit consistent prior tuberculosis infection include , limited , apical scarring , apical fibrosis , multiple calcify granulomasa . This include noncaseating granulomasa Patients close contact person active tuberculosis Patient history listeriosis tuberculosis ( unless document adequately treat ) Administration live ( attenuate ) vaccine within 3 month prior screen Visit ( eg , varicellazoster vaccine , oral polio , rabies ) Positive Hepatitis B surface antigen ( HBsAg ) positive Hepatitis B core antibody ( HBcAb ) ; and/or positive Hepatitis C antibody ( HCV ) Screening Visit Prior opportunistic infection within 6 month prior screen receive antiTNF treatment History hypersensitivity reaction , localize injection site reaction , biological molecule History current sign demyelinate disease neurological disease opinion Investigator interfere study safety assessment include assessment progressive multifocal leukoencephalopathy Patients bleed disorder know platelet dysfunction The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>